Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel + Carboplatin ± Bevacizumab followed by maintenance Niraparib ± Bevacizumab in advanced ovarian cancer after complete cytoreductive surgery
KCT0007855Phase 2Not yet recruiting
- Sponsor
- Boryung
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of niraparib in ovarian cancer (2 arms), sponsored by Boryung. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
niraparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on KCT0007855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007855.